RAD140 is a novel substance with androgenic properties that somewhat selectively supports muscle growth over prostate growth when compared with testosterone. In lower doses, it does not stimulate prostate growth according to rat study [1]. In the same study, cynomolgus monkeys were used for determining bioavailability and effective dose. Bioavailability of RAD140 is 65-75% and effective dose is 0.1 mg/kg. Therefore, it is reasonable to speculate that a dose for human clinical study would be 10 or 11 mg. There was no further increase of effect (body mass) when dose was increased tenfold to 1 mg/kg.
However, it is reasonable to speculate that the side-effects (prostate growth, endogenous testosterone suppression) could increase. As expected, it lowered the blood lipids (LDL, HDL and triglycerides), and it did not cause significant liver enzyme elevation [1]. A few years after the initial study, it was considered as a doping substance and a doping detection method was developed [2]. There are no human studies of RAD140, yet, but the preclinical resrearch suggests, tentatively, that RAD140 may have neuroprotective properties similar to testosterone [3], among other medically relevant studies [4].
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018048/
[2] https://www.ncbi.nlm.nih.gov/pubmed/23650030
[3] https://www.ncbi.nlm.nih.gov/pubmed/24428527
[4] https://www.ncbi.nlm.nih.gov/pubmed/28974548